Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Acquisitions Could Double OTC Sales By 2014

This article was originally published in The Tan Sheet

Executive Summary

French drug maker Sanofi-Aventis is establishing an OTC division and plans to double revenues from nonprescription drug products within five years
Advertisement

Related Content

People In Brief
Deals Of The Week: Sanofi, Teva, Ablexis; Kadmon Emerges From Stealth Mode
Nepentes Buy Continues Sanofi's Consumer Product Shopping Spree
Nepentes Buy Continues Sanofi Consumer Product Acquisition March
With $1.9 Bil. Bid For Chattem, Sanofi Knocks On Door To U.S. OTC Market
Sanofi Eyes Chattem As Key Building Block For Global OTC Growth
Sanofi Builds OTC Business Through Organic Growth And Bolt-Ons
Singulair Switch Among Merck's OTC Possibilities
Sanofi-Aventis acquires Mexican firm
Sanofi-Aventis Nurtures Supplement Interest With Symbion Consumer Buy

Topics

Advertisement
UsernamePublicRestriction

Register

PS102621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel